According to overseas pharmaceutical industry media Fierce Biotech, multinational pharmaceutical company AbbVie has recently filed a lawsuit against Beigene, alleging that the latter has stolen its commercial secrets related to BTK degrader. Beigene has learned about AbbVie's recent lawsuit, which includes Beigene's independently discovered compound BGB-16673. Beigene will vigorously defend against AbbVie's accusations and is currently carefully reviewing AbbVie's claims to provide an appropriate response through legal procedures. (Source)
百济神州回应遭艾伯维再次起诉：否认指控，将开展坚决辩护
Beigene responds to AbbVie's lawsuit: denies the accusations and will vigorously defend itself.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.